脂蛋白在阿尔茨海默氏病的不同发病过程中的作用:综合性综述
Xinyi Wang1, Huaqiang Li1, Yunjie Sheng1
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou 310053, Zhejiang Province, PR China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|January 6, 2024
概括
甲状腺脂 (SPLs) 在阿尔茨海默病 (AD) 进展中至关重要,影响粉样蛋白-β,和APOE4. 准SPL代谢为AD提供了一个新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 利皮多米克 (Lipidomics) 是一种消化剂.
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 和病理.
- 斯芬戈脂质 (SPLs) 是复杂的脂质,涉及神经退行性疾病.
- SPL代谢和AD病变发生之间的相互作用尚未完全理解.
研究的目的:
- 审查SPL和关键AD参与者 (Aβ,tau,α-Synuclein,APOE) 之间的神经机制相互作用.
- 探索铁化在SPL介导的AD病变发生中的作用.
- 为突出阿尔茨海默氏症诊断和治疗的新兴脂组学技术.
主要方法:
- 文献综述侧重于脂代谢和阿尔茨海默病.
- 分析Aβ,tau,α-Synuclein和APOE在与SPL相关的AD病理中的作用.
- 讨论新兴技术,如衍生和离子移动性质谱 (IM-MS) 在sphingolipidomics.
主要成果:
- SPLs与Aβ,tau,α-Synuclein和APOE进行复杂的相互作用,影响AD的发病和进展.
- 胺-α-Synuclein相互作用加速铁,加剧AD.
- 改变SPL水平会影响α-Syn积累和APOE4表达,影响AD风险.
结论:
- 甲状腺脂代谢是阿尔茨海默氏症病原发生的一个关键因素.
- 针对SPLs提供了一个有希望的,但尚未探索的AD治疗途径.
- 先进的脂组学技术对于克服阿尔茨海默病的诊断和治疗挑战至关重要.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:35Asymmetric Lipid Bilayer
7.2K
Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
7.2K
01:04Glial Cells
87.2K
Overview
87.2K